Medaus Recalls Cesium Chloride Vials Due to Sterility Concerns
Medaus, Inc. is recalling specific lots of Cesium Chloride 600mg/mL vials because the company cannot assure the sterility of the product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric for drug recalls involving potential health risks.
Plain-English summary
Medaus, Inc. is recalling Cesium Chloride 600mg/mL (PF) 10mL vials. The recall was initiated because the company lacks assurance of the sterility of the affected product.
The recall covers 506 mL in vials distributed nationwide in the U.S., as well as in Japan and New Zealand. The affected lots include 151207-10, 151222-18, 151222-20, 160210-47, 160210-49, 160215-20, 160302-45, and 160302-56.
Consumers and healthcare providers should stop using the recalled product and contact Medaus, Inc. for further instructions or a refund.
The recalled product
- Product
- CESIUM CHLORIDE 600MG/ML (PF), 10ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Pharmaceutical
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lot #: 151207-10
- BUD: 06/04/16
- Lot #: 151222-18
- BUD: 06/19/16
- Lot #: 151222-20
- Lot #: 160210-47
- BUD: 08/29/16
- Lot #: 160210-49
- Lot #: 160215-20
- BUD: 08/13/16
- Lot #: 160302-45
- Lot #: 160302-56
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMedaus Recalls Magnesium Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Pyridoxine HCL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Sodium Ascorbate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls NA Ascorbate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Taurine 50 mg/mL PF Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Testosterone Cyp 200 mg/mL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25